Research-literacy siteEducational evidence reviews only — not medical advice, not dosing guidance, not a protocol for human or animal use. Medical disclaimer.

PeptideStacks
pathway

Nitric oxide (NO) system

also: NO signalling, nitric oxide pathway, eNOS pathway, nitric oxide synthase system

A gasotransmitter signalling system in which eNOS, iNOS and nNOS enzymes make nitric oxide from L-arginine, with roles in vascular tone, platelet function and tissue repair.

Nitric oxide (NO) is a short-lived, membrane-permeable gaseous signalling molecule made from L-arginine by nitric oxide synthase (NOS) enzymes. Three NOS isoforms are described: endothelial NOS (eNOS, in blood vessel endothelium), neuronal NOS (nNOS, in nervous tissue) and inducible NOS (iNOS, raised in macrophages and other cells during inflammation). NO acts mainly by activating soluble guanylate cyclase (sGC) in target cells, which raises cyclic GMP (cGMP) and leads to relaxation of vascular smooth muscle, inhibition of platelet aggregation and changes in gene expression.

Why it matters in peptide research

NO is a regulator of tissue perfusion. When eNOS is activated in endothelial cells, for example by shear stress, VEGF or bradykinin, the NO produced diffuses to adjacent smooth muscle, relaxes the vessel wall and increases blood flow. NO is also reported to promote angiogenesis, in part by stabilising HIF-1α and stimulating VEGF expression.

The NO system is usually described as having two faces in inflammation: low-level, eNOS-derived NO is generally anti-inflammatory and cytoprotective, while high-level, iNOS-derived NO in activated macrophages contributes to oxidative stress through peroxynitrite.

The peptide most linked to this system on this site is BPC-157. Its literature is mostly rat work from one research group, and what it reports is:

  • In a 1997 rat study of ethanol-induced gastric lesions, the nitric oxide synthase blocker L-NAME attenuated the effect of BPC-157, and L-NAME plus L-arginine impaired it further. In rat stomach tissue in vitro, however, BPC-157 generated nitric oxide comparably to L-arginine and L-NAME did not inhibit that effect, even at ten times the concentration that blocked L-arginine's.
  • A 2025 narrative review of BPC-157 in musculoskeletal healing (McGuire and colleagues, Current Reviews in Musculoskeletal Medicine) says it "activates several overlapping pathways, notably VEGFR2 and nitric oxide synthesis via the Akt-eNOS axis".
  • A 2020 study from another laboratory found that BPC-157 caused endothelium-dependent relaxation of isolated rat aorta and activation of an Src-caveolin-1-eNOS pathway.

These are proposed mechanisms from animal and cell work. The papers are listed in the Sikiric lab citation map.

Peptides / stacks that act on this

  • BPC-157. FDA's page "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks" (content current as of 22 April 2026) says: "Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization." The BPC-157 page gives FDA's full entry.

Reading tip

"Nitric oxide booster" is a term used in sports-nutrition marketing, usually for L-arginine or L-citrulline supplements. Whether oral supplements meaningfully raise eNOS activity in healthy people is a separate question, and the NO mechanisms above concern the body's own signalling and the animal findings listed, not supplements.

Published: 2026-05-16Last updated: 2026-11-06
  • Correction (2026-11-06): Corrected 6 November 2026 after a dose and citation audit: the claim that BPC-157 'consistently shows NO-dependent protective effects' was replaced by what the sources report (a 1997 rat study, a 2025 review, a 2020 cell study); unsourced iNOS and L-arginine comments were removed; FDA's BPC-157 statement was added.

If you spot an error or have new evidence to suggest, please use our corrections policy.